JP2025506844A - 加齢及び加齢関連障害の治療又は予防のためのクロマノール化合物 - Google Patents

加齢及び加齢関連障害の治療又は予防のためのクロマノール化合物 Download PDF

Info

Publication number
JP2025506844A
JP2025506844A JP2024550618A JP2024550618A JP2025506844A JP 2025506844 A JP2025506844 A JP 2025506844A JP 2024550618 A JP2024550618 A JP 2024550618A JP 2024550618 A JP2024550618 A JP 2024550618A JP 2025506844 A JP2025506844 A JP 2025506844A
Authority
JP
Japan
Prior art keywords
compound according
treatment
compound
aging
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506844A5 (https=
Inventor
ロバート ヘンク ヘニング，
グイド クレニング，
デル グラーフ， アドリアヌス コルネリス ファン
ダニエル アンリ スワルト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of JP2025506844A publication Critical patent/JP2025506844A/ja
Publication of JP2025506844A5 publication Critical patent/JP2025506844A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024550618A 2022-02-28 2023-02-28 加齢及び加齢関連障害の治療又は予防のためのクロマノール化合物 Pending JP2025506844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2031091 2022-02-28
NL2031091A NL2031091B1 (en) 2022-02-28 2022-02-28 Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
PCT/NL2023/050095 WO2023163596A1 (en) 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Publications (2)

Publication Number Publication Date
JP2025506844A true JP2025506844A (ja) 2025-03-13
JP2025506844A5 JP2025506844A5 (https=) 2026-03-02

Family

ID=83271289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550618A Pending JP2025506844A (ja) 2022-02-28 2023-02-28 加齢及び加齢関連障害の治療又は予防のためのクロマノール化合物

Country Status (10)

Country Link
US (1) US20250177384A1 (https=)
EP (1) EP4486317A1 (https=)
JP (1) JP2025506844A (https=)
CN (1) CN118742301A (https=)
AU (1) AU2023225518A1 (https=)
CA (1) CA3252944A1 (https=)
CL (1) CL2024002555A1 (https=)
NL (1) NL2031091B1 (https=)
WO (1) WO2023163596A1 (https=)
ZA (1) ZA202406418B (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP2680838A1 (en) 2011-02-28 2014-01-08 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2015148522A1 (en) 2014-03-24 2015-10-01 Seals Douglas R Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
EP3672593B1 (en) * 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
US20250177384A1 (en) 2025-06-05
CN118742301A (zh) 2024-10-01
AU2023225518A1 (en) 2024-09-12
EP4486317A1 (en) 2025-01-08
NL2031091B1 (en) 2023-09-07
CL2024002555A1 (es) 2025-01-10
WO2023163596A1 (en) 2023-08-31
ZA202406418B (en) 2025-11-26
CA3252944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
ES2741439T3 (es) Compuestos aromáticos sustituidos
JP4491136B2 (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
TWI407955B (zh) 高脂血症之預防及／或治療劑
US20230372275A1 (en) Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
KR20170141757A (ko) 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
JP2019504819A (ja) 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
JP7749661B2 (ja) 心不全の処置のためのクロマノール化合物
JP2025506844A (ja) 加齢及び加齢関連障害の治療又は予防のためのクロマノール化合物
US20100234366A1 (en) Use of Strobilurins for the Treatment of Disorders of Iron Metabolism
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
CN107206007B (zh) 用于治疗肺高血压的方法
JP2015526497A (ja) 肺高血圧症の治療のためのベータ−３アドレナリン受容体アゴニストの使用
WO2020067333A1 (ja) 線維症治療用医薬組成物
HK40115454A (zh) 用於治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
JP2023529612A (ja) 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
RU2451507C2 (ru) Лекарственное средство для лечения хронического обструктивного заболевания легких
HK40121343A (zh) 治疗特发性肺纤维化的方法
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
WO2025221289A1 (en) Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor
JP2025518700A (ja) グリシン輸送阻害剤を用いて肝性ポルフィリン症を処置するための組成物および方法
HK40086505A (zh) 治疗炎性肠病的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260219